Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study-Reference-Cited by-同舟云学术

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

Published:2021-04 Issue:2 Volume:6 Page:100079
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Cascone T.,Sacks R.L.,Subbiah I.M.,Drobnitzky N.,Piha-Paul S.A.,Hong D.S.,Hess K.R.,Amini B.,Bhatt T.,Fu S.,Naing A.,Janku F.,Karp D.,Falchook G.S.,Conley A.P.,Sherman S.I.,Meric-Bernstam F.,Ryan A.J.,Heymach J.V.,Subbiah V.

Funder

The University of Texas MD Anderson Cancer Center

American Cancer Society

ASCO

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Cell signaling by receptor tyrosine kinases;Lemmon;Cell,2010

2. Oncogenic kinase signalling;Blume-Jensen;Nature,2001

3. The discovery of receptor tyrosine kinases: targets for cancer therapy;Gschwind;Nat Rev Cancer,2004

4. Acquired resistance to TKIs in solid tumours: learning from lung cancer;Camidge;Nat Rev Clin Oncol,2014

5. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors;Westover;Ann Oncol,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis;Diagnostics;2024-08-28

2. Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents;Expert Opinion on Pharmacotherapy;2024-04-12

3. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study;ESMO Open;2023-12

4. Targeted therapy for head and neck squamous cell carcinoma microenvironment;Frontiers in Medicine;2023-08-30

5. Receptor tyrosine kinase inhibitors in cancer;Cellular and Molecular Life Sciences;2023-03-22